Previous Close | 0.0118 |
Open | 0.0110 |
Bid | 0.0110 x 1100 |
Ask | 0.0115 x 1800 |
Day's Range | 0.0096 - 0.0115 |
52 Week Range | 0.0060 - 0.5490 |
Volume | |
Avg. Volume | 1,371,154 |
Market Cap | 713,694 |
Beta (5Y Monthly) | -0.74 |
PE Ratio (TTM) | 0.01 |
EPS (TTM) | 1.7400 |
Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ETSAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer, will present and host one-on-one meetings at the OTCQB Venture Virtual Investor Conference as follows: Date:Thursday, August 1, 2024Time:10:30am ETAccess Webca
Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to Phexxi® (lactic acid, citric acid, potassium bitartrate), Evofem's FDA-approved hormone-free contraceptive.
MOUNTAIN VIEW, Calif., July 17, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.’s ("Evofem") (OTCQB: EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem’s future success, including inter